PDF(Sci-hub)
Abstract：
UNASSIGNED: After initially recommending palivizumab (PVZ), a monoclonal antibody against respiratory syncytial virus (RSV) for all infants 29 to 32 weeks at birth if <6 months age at season start, the American Academy of Pediatrics (AAP) and Canadian Paediatric Society (CPS) guidelines were revised. British Columbia was the only jurisdiction in North America to restrict eligibility for this group to those with additional risk factors, long before the change in national recommendations.
UNASSIGNED: To determine the risk for first season RSV admission for 29 to 32-week gestational age (GA) infants admitted to Victoria Neonatal Intensive Care Unit (NICU) that either received or were denied PVZ prophylaxis.
UNASSIGNED: Descriptive cohort study of infants eligible for prophylaxis according to earlier CPS guidelines. Instead, BC guidelines for prophylaxis were applied and data for Vancouver Island infants were collected over 10 consecutive RSV seasons.
UNASSIGNED: We followed 423 infants. Three hundred and thirty-six (79%) did not receive prophylaxis, of which 10 (3.0%; 95% confidence interval [CI] 1.4% to 5.4%) had an RSV hospitalization before the end of April during their first RSV season versus 3 admissions from 87 (3.5%; 95% CI 0.7% to 10%) infants who received prophylaxis.
UNASSIGNED: Our risk factor approach to RSV prophylaxis for infants born at 29 to 32 weeks GA resulted in a low (average incidence=3.1%) rate of RSV hospitalization. Our approach would offer considerable cost savings to RSV prophylaxis programs that continue to offer routine prophylaxis beyond 28/29 weeks GA at birth.
UNASSIGNED: To determine the risk for first season RSV admission for 29 to 32-week gestational age (GA) infants admitted to Victoria Neonatal Intensive Care Unit (NICU) that either received or were denied PVZ prophylaxis.
UNASSIGNED: Descriptive cohort study of infants eligible for prophylaxis according to earlier CPS guidelines. Instead, BC guidelines for prophylaxis were applied and data for Vancouver Island infants were collected over 10 consecutive RSV seasons.
UNASSIGNED: We followed 423 infants. Three hundred and thirty-six (79%) did not receive prophylaxis, of which 10 (3.0%; 95% confidence interval [CI] 1.4% to 5.4%) had an RSV hospitalization before the end of April during their first RSV season versus 3 admissions from 87 (3.5%; 95% CI 0.7% to 10%) infants who received prophylaxis.
UNASSIGNED: Our risk factor approach to RSV prophylaxis for infants born at 29 to 32 weeks GA resulted in a low (average incidence=3.1%) rate of RSV hospitalization. Our approach would offer considerable cost savings to RSV prophylaxis programs that continue to offer routine prophylaxis beyond 28/29 weeks GA at birth.
摘要：
未经批准：最初推荐帕利珠单抗（PVZ）后，一种抗呼吸道合胞病毒（RSV）的单克隆抗体，适用于所有出生时29至32周的婴儿，如果季节开始时年龄<6个月，美国儿科学会(AAP)和加拿大儿科学会(CPS)指南进行了修订.不列颠哥伦比亚省是北美唯一将该组的资格限制为具有其他风险因素的人的司法管辖区，早在国家建议发生变化之前。
UNASSIGNED：为了确定在维多利亚新生儿重症监护病房（NICU）接受或拒绝PVZ预防的29至32周胎龄（GA）婴儿的第一个季节RSV入院的风险。
UNASSIGNED：根据早期CPS指南对符合预防条件的婴儿进行描述性队列研究。相反，应用了BC预防指南，并在连续10个RSV季节收集了温哥华岛婴儿的数据。
未经评估：我们跟踪了423名婴儿。三百三十六（79％）没有接受预防，其中10例(3.0%;95%置信区间[CI]1.4%~5.4%)在4月底前首次RSV季节住院,而接受预防的婴儿中有3例(3.5%;95%CI0.7%~10%)入院.
UNASSIGNED：我们对29至32周出生的GA婴儿进行RSV预防的危险因素方法导致RSV住院率较低（平均发生率=3.1％）。我们的方法将为RSV预防计划提供可观的成本节省，这些计划在出生时继续提供超过28/29周的常规预防。
UNASSIGNED：为了确定在维多利亚新生儿重症监护病房（NICU）接受或拒绝PVZ预防的29至32周胎龄（GA）婴儿的第一个季节RSV入院的风险。
UNASSIGNED：根据早期CPS指南对符合预防条件的婴儿进行描述性队列研究。相反，应用了BC预防指南，并在连续10个RSV季节收集了温哥华岛婴儿的数据。
未经评估：我们跟踪了423名婴儿。三百三十六（79％）没有接受预防，其中10例(3.0%;95%置信区间[CI]1.4%~5.4%)在4月底前首次RSV季节住院,而接受预防的婴儿中有3例(3.5%;95%CI0.7%~10%)入院.
UNASSIGNED：我们对29至32周出生的GA婴儿进行RSV预防的危险因素方法导致RSV住院率较低（平均发生率=3.1％）。我们的方法将为RSV预防计划提供可观的成本节省，这些计划在出生时继续提供超过28/29周的常规预防。
